IG
IGC.US IGC Pharma, Inc.
- Market cap
- USD 20.5M
- P/E
- -
- P/B
- 3.16x
- ROE
- -153.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is IGC.US undervalued?
Graham numberThe Graham number of IGC Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IGC Pharma, Inc. fundamental analysis
No fundamental analysis for IGC Pharma, Inc. yet.
IGC Pharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, th…
Full company profileIGC Pharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IGC Pharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 580K | 2.19M | 5.12M | 4.07M | 898K | 397K | 911K | 1.35M | 1.27M | 1.19M | 1.19M |
| Gross Profit | 218K | 81.5K | 132K | 115K | -349K | 194K | -158K | 733K | 619K | 352K | 218K |
| Operating Income | -2.05M | -1.79M | -4.64M | -6.86M | -8.72M | -15.4M | -11.6M | -9.80M | -7.45M | -10.2M | -9.43M |
| EBITDA | -1.22M | -1.74M | -4.58M | -6.72M | -8.33M | -14.4M | -10.8M | -12.4M | -6.50M | -6.49M | -9.55M |
| Net Income | -1.87M | -1.79M | -4.10M | -7.32M | -8.81M | -15.0M | -11.5M | -13.0M | -7.12M | -6.55M | -9.96M |
| EPS | -0.07 | -0.06 | -0.12 | -0.19 | -0.21 | -0.30 | -0.22 | -0.22 | -0.09 | -0.07 | -0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 11.3M | 10.9M | 34.5M | 29.0M | 35.9M | 26.8M | 17.2M | 9.90M | 8.75M | 9.19M | 9.73M |
| Total Liabilities | 3.93M | 2.79M | 893K | 2.45M | 3.06M | 2.94M | 2.27M | 2.58M | 2.42M | 3.06M | 3.23M |
| Shareholders' Equity | 7.35M | 8.06M | 33.6M | 26.5M | 32.8M | 23.9M | 14.9M | 7.32M | 6.33M | 6.12M | 6.50M |
| Cash & Short-term Investments | 2.42M | 1.66M | 25.6M | 12.3M | 14.6M | 10.5M | 3.35M | 1.20M | 405K | 235K | 413K |
| Total Debt | 2.64M | 2.23M | 50.0K | 624K | 1.08M | 611K | 481K | 345K | 241K | 926K | 869K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.39M | -1.93M | -3.33M | -8.68M | -10.8M | -7.46M | -7.05M | -5.20M | -4.80M | -5.94M | -5.53M |
| Capital Expenditure | 146K | 201K | 60.0K | 4.47M | 1.59M | 771K | 619K | 515K | 482K | 164K | 396K |
| Free Cash Flow | -1.54M | -2.13M | -3.39M | -13.1M | -12.4M | -8.23M | -7.67M | -5.71M | -5.28M | -6.11M | -5.93M |
| Ratios | |||||||||||
| ROE | -25.4% | -22.1% | -12.2% | -27.6% | -26.9% | -62.8% | -77.2% | -177.6% | -112.5% | -107.0% | -153.3% |
| ROA | -16.5% | -16.5% | -11.9% | -25.2% | -24.6% | -56.0% | -67.0% | -131.3% | -81.4% | -71.3% | -102.4% |
| Net Profit Margin | -321.7% | -81.4% | -80.1% | -179.6% | -981.2% | -3,782.4% | -1,263.0% | -966.5% | -560.3% | -552.1% | -840.1% |
| Debt to Equity | 0.36x | 0.28x | 0.00x | 0.02x | 0.03x | 0.03x | 0.03x | 0.05x | 0.04x | 0.15x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IGC Pharma, Inc. dividends
IGC Pharma, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 19, 2013.
Who owns IGC Pharma, Inc.
- Insiders 9.17%
- Institutions 19.75%
- Public & others 71.08%
- Shares outstanding 117M
- Free float 92.4M
IGC Pharma, Inc. company profile
- Company name
- IGC Pharma, Inc.
- Ticker
- IGC.US
- Exchange
- USA Stocks
- Listed since
- Apr 13, 2006
- Sector
- Healthcare
- Industry
- Trading Companies & Distributors
- Employees
- 70
- Fiscal year end
- March
- Address
- 10224 Falls Road, Potomac, MD, United States, 20854
- Phone
- 301 983 0998
- Website
- igcpharma.com
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc. management
4- Mr. Ram MukundaFounder, President, CEO & Director · born 1959
- Ms. Claudia GrimaldiVP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director · born 1971
- Benysh Qureshi Esq., M.B.A.Director of Operations
- Mr. Rohit Goel CPA, M.B.A.Director of Accounting & Senior Director · born 1994